Shots: CRISPR to gain access to KSQ intellectual property (IP) for editing certain novel gene targets in its allogeneic oncology cell therapy programs while KSQ will get access to CRISPR’ […]readmore
Tags : Cross-Licensing Agreement
Shots: Editas & BlueRock enter in to research collaboration to develop engineered cell therapies/ allogeneic pluripotent stem cell (PSC) lines by the combination of Editas’ CRISPR & BlueRock’s iPSC in […]readmore